Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 764,520 shares of the biopharmaceutical company’s stock after acquiring an additional 211,493 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.06% of Gilead Sciences worth $64,097,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of GILD. Legal & General Group Plc lifted its stake in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Gilead Sciences by 2.6% during the second quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock valued at $714,421,000 after purchasing an additional 268,208 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Gilead Sciences by 24.7% during the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after purchasing an additional 1,564,792 shares in the last quarter. Van ECK Associates Corp raised its position in Gilead Sciences by 0.4% in the third quarter. Van ECK Associates Corp now owns 6,342,831 shares of the biopharmaceutical company’s stock worth $553,285,000 after acquiring an additional 22,847 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in Gilead Sciences by 19.6% in the second quarter. Federated Hermes Inc. now owns 6,321,167 shares of the biopharmaceutical company’s stock worth $433,695,000 after acquiring an additional 1,036,932 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $89.84 on Friday. The stock’s fifty day moving average is $87.28 and its 200-day moving average is $76.61. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market capitalization of $111.96 billion, a PE ratio of 998.22, a PEG ratio of 2.72 and a beta of 0.17. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.29 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post 4.38 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.43%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on GILD shares. Truist Financial boosted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Royal Bank of Canada boosted their target price on Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a report on Monday. Citigroup began coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Finally, JPMorgan Chase & Co. upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $95.41.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.